BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye T, Zhang J, Wu D, Shi J, Kuang Z, Ma Y, Xu Q, Chen B, Kan C, Sun X, Han F. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis. Front Endocrinol 2022;13:907984. [DOI: 10.3389/fendo.2022.907984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi J, Qiu H, Xu Q, Ma Y, Ye T, Kuang Z, Qu N, Kan C, Hou N, Han F, Sun X. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice. iScience 2023;26:105816. [PMID: 36636340 DOI: 10.1016/j.isci.2022.105816] [Reference Citation Analysis]
2 Chen X, Wang J, Lin Y, Liu Y, Zhou T. Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors. Cells 2022;11. [PMID: 36497173 DOI: 10.3390/cells11233913] [Reference Citation Analysis]
3 Chen CL, Lin YC. Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target. Int J Mol Sci 2022;23:10055. [PMID: 36077452 DOI: 10.3390/ijms231710055] [Reference Citation Analysis]